Study to Assess the Efficacy and Safety of the Epigenetic Modifying Effects of CC-486 (Oral Azacitidine) in Combination With Fulvestrant
Status: TERMINATED
Study type: INTERVENTIONAL
Conditions: Breast Neoplasms
Interventions: DRUG: CC-486|DRUG: Fulvestrant
Sponsor: Celgene